Thrivent Financial for Lutherans
STRO icon

Thrivent Financial for Lutherans’s Sutro Biopharma STRO Stock Holding History

Thrivent Financial for Lutherans’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,710
Closed -$178K – 2536
2024
Q4 		$178K Buy
+9,710
New +$296K ﹤0.01% 2521

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Thrivent Financial for Lutherans's STRO Position: Q1 2025 in Review

Thrivent Financial for Lutherans sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 9,710 shares — an estimated $178K sold.

Thrivent Financial for Lutherans first reported a position in STRO in Q4 2024 and held it in 1 quarter. The position peaked at $178K in Q4 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Thrivent Financial for Lutherans reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 9,710 Sutro Biopharma shares in Q1 2025, an estimated $178K.
  • Thrivent Financial for Lutherans first reported a position in Sutro Biopharma in Q4 2024 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Sutro Biopharma position peaked at $178K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2025, filed 13 May 2025.